Astellas Pharma to acquire stake in biotech company Taysha GeneTherapies
Astellas Pharma has signed an agreement to acquire a 15% stake in US-based biotech company Taysha GeneTherapies through an investment of $50 million. As part of the transaction, the Japanese pharmaceutical company will get an exclusive option to license Taysha GeneTherapies’ TSHA-102 and TSHA-120, two clinical-stage, single-gene therapies for rare genetic diseases. TSHA-102 is a […]